Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 780	$ 1,908
Loan receivable from Emergence Global Enterprises Inc. - related party	17,901	17,901
Total current assets	18,681	19,809
Other assets
Other receivable	71,269	113,999
Note receivable - CEN Biotech Ukraine LLC - related party	44,859	44,859
Advances to CEN Biotech Ukraine LLC - related party	1,229,328	1,179,328
Intangible assets, net	4,849,944	4,956,147
Total assets	6,214,081	6,314,142
Current liabilities
Accounts payable	221,001	190,716
Accounts payable – related parties	8,347	8,347
Loans payable	531,152	527,379
Loans payable – related parties	1,363,831	1,363,354
Convertible notes payable	6,763,275	6,652,448
Convertible notes payable- related parties	2,558,681	2,558,681
Accrued interest	1,237,430	1,125,034
Accrued interest – related parties	1,696,874	1,615,880
Lease liabilities	29,659	22,895
Accrued expenses	658,833	641,023
Total current liabilities	15,069,083	14,705,757
Operating lease liabilities, less current portion	140,510	142,102
Patent acquisition liability	1,380,000	1,380,000
Convertible notes, less current portion	88,000	78,000
Total liabilities	16,677,593	16,305,859
Shareholders’ deficit
Common stock; unlimited authorized shares; 27,610,732 and 27,557,363 issued and outstanding as of March 31, 2021 and December 31, 2020, respectively. No par value.
Additional paid-in capital	17,220,050	17,068,810
Accumulated deficit	(27,683,562)	(27,060,527)
Total shareholders’ deficit	(10,463,512)	(9,991,717)
Total liabilities and shareholders’ deficit	$ 6,214,081	$ 6,314,142